ALLK Allakos Inc

Price (delayed)

$3.46

Market cap

$189.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.4

Enterprise value

$154.91M

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab ...

Highlights
Allakos's debt has decreased by 4.7% YoY
ALLK's EPS has dropped by 93% year-on-year but it is up by 2.2% since the previous quarter
The net income has plunged by 102% YoY
The company's quick ratio has shrunk by 65% YoY and by 11% QoQ

Key stats

What are the main financial stats of ALLK
Market
Shares outstanding
54.84M
Market cap
$189.76M
Enterprise value
$154.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.85
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$403.55M
EBITDA
-$395.93M
Free cash flow
-$349.32M
Per share
EPS
-$7.4
Free cash flow per share
-$6.37
Book value per share
$4.07
Revenue per share
$0
TBVPS
$5.6
Balance sheet
Total assets
$306.91M
Total liabilities
$84.1M
Debt
$47.6M
Equity
$222.81M
Working capital
$185.36M
Liquidity
Debt to equity
0.21
Current ratio
6.08
Quick ratio
5.82
Net debt/EBITDA
0.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-89.2%
Return on equity
-111%
Return on invested capital
-123.4%
Return on capital employed
-149.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLK stock price

How has the Allakos stock price performed over time
Intraday
-4.16%
1 week
-9.66%
1 month
-4.16%
1 year
-95.92%
YTD
-64.66%
QTD
10.54%

Financial performance

How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$403.46M
Net income
-$403.22M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 102% YoY
The operating income has plunged by 102% YoY

Growth

What is Allakos's growth rate over time

Valuation

What is Allakos stock price valuation
P/E
N/A
P/B
0.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS has dropped by 93% year-on-year but it is up by 2.2% since the previous quarter
ALLK's price to book (P/B) is 89% less than its 5-year quarterly average of 7.8 and 76% less than its last 4 quarters average of 3.5
The equity has dropped by 61% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Allakos business performance
The ROIC has plunged by 185% YoY and by 15% from the previous quarter
The return on assets has dropped by 180% year-on-year and by 17% since the previous quarter
ALLK's return on equity is down by 21% since the previous quarter

Dividends

What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLK.

Financial health

How did Allakos financials performed over time
The company's quick ratio has shrunk by 65% YoY and by 11% QoQ
The current ratio has shrunk by 64% YoY and by 11% QoQ
Allakos's debt is 79% less than its equity
ALLK's debt to equity has soared by 133% YoY and by 11% from the previous quarter
The equity has dropped by 61% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.